Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Radiotherapy 35Doxorubicin 30Ifosfamide 29Cyclophosphamide 24Vincristine 23Filgrastim 23Etoposide 20Temozolomide 14Granulocyte Colony-Stimulating Factor 14Dactinomycin 11Cisplatin 11Trabectedin 10Methotrexate 10Gene Expression Profiling 10Radiation 9Imatinib Mesylate 9Surgical Procedures, Operative 8Polymerase Chain Reaction 8Irinotecan 8Specimen Handling 7Paclitaxel 7Chemotherapy, Adjuvant 7Mesna 6Immunohistochemistry 6Gemcitabine 6Carmustine 6Biopsy 6sargramostim 5pegfilgrastim 5etoposide phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Dalteparin × Sarcoma × Clear all
NCT00028678 2023-06-18

Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Eastern Cooperative Oncology Group

Phase 2 Completed
45 enrolled
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡